|  |
| --- |
| CASE 1 |
|  |
| Tumor Description | **Grade** | **Tumor Size** |
| Primary Site | C76.0 | **Clinical** | 9 | **Clinical** | 000 |
| Laterality | 0 | **Pathological** | 9 | **Pathological** | 999 |
| Histology | 8070 | **Post Therapy (yc)**  | Blank | **Summary** | 000 |
| Behavior | 3 | **Post Therapy (yp)**  | Blank |   |
| AJCC Staging Items |
| Clinical T  | cT0 | **Pathological T** | blank | **Post-therapy cT** |   | **Post-therapy pT** |   |
| cT Suffix  | Blank | **pT Suffix** | blank | **ypT Suffix** |   | **ypT Suffix** |   |
| Clinical N  | cN2b | **Pathological N** | blank | **Post-therapy cN** |   | **Post-therapy pN** |   |
| cN Suffix  | (f) | **pN Suffix** | blank | **ypN Suffix** |   | **ypN Suffix** |   |
| Clinical M  | cM0 | **Pathological M** | blank | **Post-therapy M** |   | **Post-therapy M** |   |
| Stage Group  | 4A | **Stage Group** | 99 | **Stage Group** |   | **Stage Group** |   |
| SS2018/EOD |
| Summary Stage 2018  | 3 |   |
| Extent of Disease |
| EOD Primary Tumor | 800 | **EOD Regional Nodes** | 250 | **EOD Mets** | 00 |

|  |  |
| --- | --- |
| Regional Nodes Positive | 95 |
| Regional Nodes Examined | 95 |
| SSDI | **LN H/N VI-VII** |  **0** | **LN H/N Other** |  0 |
| Schema Discriminator 1 | 3 | **ENE Pathological** | X.9 | LN H/N levels I-III | 2 |
| ENE Clinical | 0 | **LN Size of Mets** | 28.0 | LN H/N levels IV-V | 0 |
| Treatment |
| Surgery Codes | **Systemic Therapy Codes** |
| Diagnostic Staging Procedure | 00 | **Chemotherapy** | 02 |
| Surgical Procedure of Primary Site | 00 | **Hormone Therapy** | 00 |
| Scope of RLN Node Surgery | 1 | **Immunotherapy** | 00 |
| Radiation |
| Phase | 1 2 3 |  | 1 2 3 |
| Primary Treatment Volume | 29 29 29 | **Dose Per fraction** | 00200 00180 00160 |
| Draining LN  | 01 01 01 | **Fractions** | 035 035 035 |
| Modality | 02 02 02 | Total Dose | 007000 006300 005600 |
| EB Planning Technique | 05 05 05 |  |  |

|  |
| --- |
| CASE 2 |
| Tumor Description | **Grade** | **Tumor Size** |
| Primary Site | C10.9 | **Clinical** | 9 | **Clinical** | 023 |
| Laterality | 0 | **Pathological** | 9 | **Pathological** | 999 |
| Histology | 8085 | **Post Therapy (yc)**  |  | **Summary** | 023 |
| Behavior | /3 | **Post Therapy (yp)**  |  |   |
| AJCC Staging Items |
| Clinical T  | cT2 | **Pathological T** |  | **Post-therapy cT** |   | **Post-therapy pT** |   |
| cT Suffix  |  | **pT Suffix** |  | **ypT Suffix** |   | **ypT Suffix** |   |
| Clinical N  | cN1 | **Pathological N** |  | **Post-therapy cN** |   | **Post-therapy pN** |   |
| cN Suffix  | (f) | **pN Suffix** |  | **ypN Suffix** |   | **ypN Suffix** |   |
| Clinical M  | cM0 | **Pathological M** |  | **Post-therapy M** |   | **Post-therapy M** |   |
| Stage Group  | 1 | **Stage Group** | 99 | **Stage Group** |   | **Stage Group** |   |
| SS2018/EOD |
| Summary Stage 2018  | 3 |   |
| Extent of Disease |
| EOD Primary Tumor | 100 | **EOD Regional Nodes** | 300 | **EOD Mets** | 00 |

|  |  |
| --- | --- |
| Regional Nodes Positive | 95 |
| Regional Nodes Examined | 95 |
| SSDIs |
| Schema Discriminator 2 | 2 | **ENE Pathological** | X.9 |
| ENE Clinical | 1 | **LN Size of Mets** | 40.0 |
| Treatment |
| Surgery Codes | **Systemic Therapy Codes** |
| Diagnostic Staging Procedure | 00 | **Chemotherapy** | 02 |
| Surgical Procedure of Primary Site | 00 | **Hormone Therapy** | 00 |
| Scope of Regional Lymph Node Surgery | 1 | **Immunotherapy** | 00 |
| Radiation |
| Primary Treatment Volume | 22 22 | **Dose per FX** | 00200 00200 |
| Draining LN | 01 01 | **Fractions** | 020 015 |
| Modality  | 03 03 | **Total Dose** | 004000 003000 |
| EB Planning technique | 05 05 |  |  |

|  |
| --- |
| CASE 3 |
| Tumor Description | **Grade** | **Tumor Size** |
| Primary Site | C09.9 | **Clinical** | 9 | **Clinical** | 999 |
| Laterality | 1 | **Pathological** | C | **Pathological** | 010 |
| Histology | 8085 | **Post Therapy (yc)**  |  | **Summary** | 010 |
| Behavior | /3 | **Post Therapy (yp)**  |  |   |
| AJCC Staging Items |
| Clinical T  | cT1 | **Pathological T** | pT1 | **Post-therapy cT** |   | **Post-therapy pT** |   |
| cT Suffix  |  | **pT Suffix** |  | **ypT Suffix** |   | **ypT Suffix** |   |
| Clinical N  | cN1 | **Pathological N** | pN2 | **Post-therapy cN** |   | **Post-therapy pN** |   |
| cN Suffix  | (f) | **pN Suffix** |  | **ypN Suffix** |   | **ypN Suffix** |   |
| Clinical M  | cM0 | **Pathological M** | cM0 | **Post-therapy M** |   | **Post-therapy M** |   |
| Stage Group  | I | **Stage Group** | 2 | **Stage Group** |   | **Stage Group** |   |
| SS2018/EOD |
| Summary Stage 2018  | 3 |   |
| Extent of Disease |
| EOD Primary Tumor | 100 | **EOD Regional Nodes** | 500 | **EOD Mets** | 00 |

|  |  |
| --- | --- |
| Regional Nodes Positive | 07 |
| Regional Nodes Examined | 26 |
| SSDIs |
| Schema Discriminator 2 | 2 | **ENE Pathological** | X.1 |
| ENE Clinical | 0 | **LN Size of Mets** | 30.0 |
| Treatment |
| Surgery Codes | **Systemic Therapy Codes** |
| Diagnostic Staging Procedure | 00 | **Chemotherapy** | 02 |
| Surgical Procedure of Primary Site | 31 | **Hormone Therapy** | 00 |
| Scope of Regional Lymph Node Surgery | 5 | **Immunotherapy** | 00 |
| Radiation |
| Primary Treatment Volume | 22 22 | **Dose per FX** | 00200 00180 |
| Draining LN | 01 01 | **Fractions** | 030 030 |
| Modality  | 02 02 | **Total Dose** | 006000 005400 |
| EB Planning technique | 05 05 |  |  |